Next says no-deal Brexit tariffs could save £15M to benefit shoppers
Category: #headlines  By Nikita Chaurasia  Date: 2019-03-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Next says no-deal Brexit tariffs could save £15M to benefit shoppers

The latest move comes in the wake of the company’s increasing focus on web sales, as it is expected to close around 507 stores over the next 15 years

Next, the fashion retail giant, has announced that after a no-deal Brexit it could save up to £15M with benefits from lower trade tariffs, that could be passed on to the consumers.

Next’s Chief Executive, Lord Simon Wolfson mentioned that consumers are not aware of the daily swings in the political debate and their purpose is to provide them improvements in the cost price, in the form of best pricing.

Citing reliable sources, in February the retail sales showed an increment of 0.4% despite surveys suggesting there is a downfall in consumer confidence. Next had reported a 0.4% fall in pre-tax profits to £722.9m for the 12 months to the end of January. In high street sales, a 7.9% plunge was countered by a 14.7% increment in online revenues.

According to Lord Wolfson, there is no proof regarding the uncertainty that Brexit is affecting consumer behaviour in this sector or not. He claimed Brexit was showing very slight negative impact on the business.

Lord Wolfson said that despite the uncertainty, the economic fundamentals that are affecting consumer behaviour have refined so far, by improved job rates and low inflation.

The latest move comes in the wake of the company’s increasing focus on web sales, as it is expected to close around 507 stores over the next 15 years.

As per Next’s prospective the business’s future is focused on advancing in online sales but around half of the online orders are carried out through a click-and-collect service, with over 80% of returns being completed in store.

The main reason behind this is that every £1 business that is migrated to online costs an additional 6p to Next, which is resulting in undermined profits. Still, advancements in online sales are exponentially well while restructuring costs are set to stay for a while, but Next’s track record suggests that it can bring up the profits by the end of the phase.  

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...